Barthel, Ernst, Dr. Harmonische Astronomie

E, Barthel

doi:10.1515/kant-1917-0145

Cited by 9 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an animal model of fibrosarcoma, it was reported that FLT uptake decreased early after antiproliferative treatment with 5-fluorouracil or cisplatin (29,30). In a mouse lymphoma xenotransplant model, significant decrease of FLT uptake was observed already 48 hours after chemotherapy with cyclophosphamide (31).…”

Section: Discussionmentioning

confidence: 99%

Molecular Imaging of Proliferation in Malignant Lymphoma

Buck¹,

Bommer²,

et al. 2006

View full text Add to dashboard Cite

We have determined the ability of positron emission tomography (PET) with the thymidine analogue 3 ¶-deoxy-3 ¶-[18 F]fluorothymidine (FLT) to detect manifestation sites of malignant lymphoma, to assess proliferative activity, and to differentiate aggressive from indolent tumors. In this prospective study, FLT-PET was done additionally to routine staging procedures in 34 patients with malignant lymphoma. Sixty minutes after i.v. injection of f330 MBq FLT, emission and transmission scanning was done. Tracer uptake in lymphoma was evaluated semiquantitatively by calculation of standardized uptake values (SUV) and correlated to tumor grading and proliferation fraction as determined by Ki-67 immunohistochemistry. FLT-PET detected a total of 490 lesions compared with 420 lesions revealed by routine staging. In 11 patients with indolent lymphoma, mean FLT-SUV in biopsied lesions was 2.3 (range, 1.2-4.5). In 21 patients with aggressive lymphoma, a significantly higher FLT uptake was observed (mean FLT-SUV, 5.9; range, 3.2-9.2; P < 0.0001) and a cutoff value of SUV = 3 accurately discriminated between indolent and aggressive lymphoma. Linear regression analysis indicated significant correlation of FLT uptake in biopsied lesions and proliferation fraction (r = 0.84; P < 0.0001). In this clinical study, FLT-PET was suitable for imaging malignant lymphoma and noninvasive assessment of tumor grading. Due to specific imaging of proliferation, FLT may be a superior PET tracer for detection of malignant lymphoma in organs with high physiologic fluorodeoxyglucose uptake and early detection of progression to a more aggressive histology or potential transformation.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular Imaging of Proliferation in Malignant Lymphoma

Buck¹,

Bommer²,

et al. 2006

View full text Add to dashboard Cite

show abstract

“…To provide biochemical evidence that the 5 ¶-phosphate was the peak identified on the HPLC chromatogram, cultured cells were treated with alkaline phosphatase as described previously (32). Briefly, HCT116 cells were grown in 100 mm dishes in triplicate and incubated with 5.0 MBq FCH for 60 min at 37jC to form the putative FCH-phosphate.…”

Section: Radiopharmaceuticalsmentioning

confidence: 99%

[18F]Fluoromethyl-[1,2-2H4]-Choline: A Novel Radiotracer for Imaging Choline Metabolism in Tumors by Positron Emission Tomography

et al. 2009

View full text Add to dashboard Cite

18 F]fluoromethylcholine, respectively (P = 0.04). D4-FCH was also found to be a useful response biomarker. Treatment with the mitogenic extracellular kinase inhibitor PD0325901 resulted in a reduction in tumor radiotracer uptake that occurred in parallel with reductions in choline kinase A expression. In conclusion, D4-FCH is a very promising metabolically stable radiotracer for imaging choline metabolism in tumors.

show abstract

“…Recently, in vitro and animal studies already suggested the use of FLT for therapeutic monitoring (34). In an animal model of fibrosarcoma, it was reported that FLT uptake decreased early after antiproliferative treatment with 5-fluorouracil or cisplatin (42,43). In a mouse lymphoma xenotransplant model, significant decrease of FLT uptake was observed already 48 h after chemotherapy with cyclophosphamide (34).…”

mentioning

confidence: 99%

Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma

Herrmann¹,

Wieder

Buck³

et al. 2007

Clinical Cancer Research

143

153

View full text Add to dashboard Cite

Purpose: To evaluate 3 ¶-deoxy-3 ¶-[18 F]fluorothymidine-positron emission tomography (FLT-PET) for early monitoring response of high-grade non-Hodgkin's lymphoma to treatment with cyclophosphamide-adriamycin-vincristine-prednisone chemotherapy with or without rituximab immunotherapy (R-CHOP/CHOP). Experimental Design: Twenty-two patients with histologically proven high-grade nonHodgkin's lymphoma scheduled to undergo first line treatment with R-CHOP/CHOP were included. All patients received baseline imaging before therapy with FLT-PET. For noninvasive assessment of treatment response, FLT-PET was repeated at following time points: group 1 (n = 6), 1and 6 weeks after R-CHOP/CHOP; group 2 (n = 16), 2 days after rituximab and 2 days after CHOP application. Emission images were acquired 45 min after injection of 300 to 370 MBq of FLT. FLT uptake was quantified by region-of-interest technique on a lesion basis. Maximum standardized uptake values (SUV) for FLT were calculated using circular region of interest (diameter, 1.5 cm). Results: In all patients, morphologically proven lesions showed initially high FLT uptake (mean SUV, 8.1 F 3.9). In group 1, mean FLT SUV decreased 7 days after R-CHOP/CHOP by 77% (P < 0.001), the reduction in FLT SUV from baseline was 85% after 40 days (P = 0.003). In group 2, FLTuptake in patients without dexamethasone pretreatment revealed no significant reduction after rituximab (P = 0.3) but significantly decreased 2 days after CHOP to 32% compared with the baseline value (P = 0.004). Conclusions: Administration of R-CHOP/CHOP is associated with an early decrease in lymphoma FLT uptake. Interestingly, there was no reduction of FLT uptake after rituximab alone, indicating no early antiproliferative effect of immunotherapy. FLT-PET seems to be promising for early evaluation of drug effects in lymphoma.The standard therapy for high-grade non-Hodgkin's lymphoma is cyclophosphamide-adriamycin-vincristine-prednisone (CHOP) or CHOP-like regimens. The introduction of the chimeric monoclonal anti-CD20 antibody rituximab to standard chemotherapy has been shown to significantly improve both event-free as well as overall survival (1, 2). In contrast to its role in combination therapies, rituximab itself does not reveal a major cytotoxic effect as a single agent on high-grade non-Hodgkin's lymphoma (3).To evaluate antitumor efficacy and possible mechanisms of action in vivo, therapy monitoring plays a major role for evaluation of new therapeutic approaches. For the last decades, helical computed tomography (CT) has represented the gold standard for staging and restaging of non-Hodgkin's lymphoma. However, definition of response criteria based on conventional radiographic characteristics remains difficult because patients treated with chemotherapy often present with residual masses of uncertain significance. Especially differentiation between fibrotic tissue and viable tumor by CT is only of limited accuracy (4 -10).Positron emission tomography using the glucose analogue 2-[18 F]fluoro-2-deox...

show abstract

Barthel, Ernst, Dr. Harmonische Astronomie

Cited by 9 publications

References 0 publications

Molecular Imaging of Proliferation in Malignant Lymphoma

Molecular Imaging of Proliferation in Malignant Lymphoma

[18F]Fluoromethyl-[1,2-2H4]-Choline: A Novel Radiotracer for Imaging Choline Metabolism in Tumors by Positron Emission Tomography

Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma

Contact Info

Product

Resources

About